



ASX Release
28th July 2025

Compumedics signs \$24m, 4-year Distribution Agreements in Asia

Highlights

- Two new 4-year distribution agreements in China signed with long-term partners:
 - \$20m agreement with sleep diagnostics distributor in Northern China
 - \$4.4m agreement with sleep and neurological distributor in Eastern China
- Both agreements include a minimum +10% per annum growth commitment

Compumedics Limited (ASX: CMP), a leading global medical device company specialising in sleep, brain, and ultrasonic blood flow monitoring, today announced the signing of two new 4-year distribution agreements with long-standing partners in China.

The agreements, valued at A\$24.4 million in total, further strengthen Compumedics' presence across key regions in Asia. The first, a A\$20 million agreement, extends the Company's established partnership with its long-term Northern China distributor focused on sleep diagnostics. The second, valued at A\$4.4 million, renews a long-standing relationship with an Eastern China distributor focused on sleep and neurology. Both agreements include a minimum +10% per annum growth commitment, providing a clear trajectory for expanding sales in one of Compumedics' most strategically important markets where Compumedics has had a significant involvement for over 20 years.

This growth reflects the Company's continued strategic shift toward a more diversified and resilient revenue base, both geographically and across product lines. The strengthening of key relationships in Asia, particularly in China, reinforces Compumedics' ability to drive consistent growth through its core sleep and neurology platforms. With a solid foundation in place and demand accelerating across multiple international markets, Compumedics remains well positioned to scale efficiently and deliver sustained, profitable growth into FY26 and beyond.

Executive Chairman and CEO Dr David Burton commented:

“These agreements demonstrate the strong momentum behind the step-change underway at Compumedics, a shift focused on profitable growth, recurring revenue, and geographic diversification. China remains a key engine for expansion, and these multi-year contracts secure predictable, growing revenues in one of our most strategically important markets. Coupled with increasing traction in the US and across our connected platforms, we are now scaling a more focused, cash-generative global business.”

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia’s Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton

Executive Chairman, CEO

P: +61 3 8420 7300

F: +61 3 8420 7399

David Lawson

Director, CFO

P: + 61 3 8420 7300

F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited’s Board of Directors